Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 3, 2018Journal of Clinical Oncology

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3

View Full Paper
Ask AI
Bookmark
Share

Authors

Dennis J. Slamon
Dennis J. SlamonUniversity College DublinPNPatrick NevenUniversitair Ziekenhuis LeuvenSCStephen ChiaBC Cancer Agency

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Slamon et al. (2018) studied this question.

synapsesocial.com/papers/69d89a5d183921ebcaae2cbchttps://doi.org/10.1200/jco.2018.78.9909
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer2016 · 2,071 citations
  2. 2PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro2009 · 1,438 citations
  3. 3Comprehensive molecular portraits of human breast tumours2012 · 12,630 citations
  4. 4Comprehensive molecular portraits of human breast tumours2012 · 12,659 citations
  5. 5MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy2017 · 1,709 citations